This bill would streamline the federal review process for biosimilar drugs, which are biological medications designed to be nearly identical to existing approved drugs. The legislation amends the Public Health Service Act by removing one requirement from the current biosimilar approval pathway and reorganizing the remaining provisions. Biosimilars are generally less expensive alternatives to brand-name biological medications, so streamlining their approval could potentially help patients access more affordable treatment options and increase competition in the pharmaceutical market. The bill directly affects the Food and Drug Administration's review process and the pharmaceutical companies seeking to bring biosimilar products to market. No specific funding amounts or implementation timelines are specified in this legislation.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.